

Vidal Essebag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232299/publications.pdf>

Version: 2024-02-01

110
papers

4,871
citations

147801

31
h-index

98798

67
g-index

110
all docs

110
docs citations

110
times ranked

4975
citing authors

#	ARTICLE	IF	CITATIONS
1	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. <i>New England Journal of Medicine</i> , 2016, 375, 111-121.	27.0	616
2	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 368, 2084-2093.	27.0	482
3	Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2021, 384, 305-315.	27.0	417
4	Frequency and Causes of Implantable Cardioverter-Defibrillator Therapies: Is Device Therapy Proarrhythmic?. <i>American Journal of Cardiology</i> , 2006, 97, 1255-1261.	1.6	212
5	Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. <i>BMC Medical Research Methodology</i> , 2005, 5, 5.	3.1	191
6	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
7	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
8	The nested case-control study in cardiology. <i>American Heart Journal</i> , 2003, 146, 581-590.	2.7	145
9	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
10	Comparative Effectiveness of Rhythm Control vs Rate Control Drug Treatment Effect on Mortality in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2012, 172, 997-1004.	3.8	126
11	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	2.8	94
12	Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillation. <i>European Heart Journal</i> , 2005, 26, 2550-2555.	2.2	89
13	Complications Associated With Revision of Sprint Fidelis Leads. <i>Circulation</i> , 2010, 121, 2384-2387.	1.6	88
14	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	1.7	84
15	Long-Term Outcomes After Ablation for Paroxysmal Atrial Fibrillation Using the Second-Generation Cryoballoon. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 306-314.	3.2	72
16	A Systematic Review and Meta-analysis of the Association Between Implantable Cardioverter-Defibrillator Shocks and Long-term Mortality. <i>Canadian Journal of Cardiology</i> , 2015, 31, 270-277.	1.7	69
17	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 105-115.	3.2	63
18	Substrate-guided ablation of haemodynamically tolerated and intolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. <i>Europace</i> , 2015, 17, 461-467.	1.7	62

#	ARTICLE	IF	CITATIONS
19	Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation. <i>Heart Rhythm</i> , 2015, 12, 1979-1986.	0.7	60
20	Assessment and Management of the Left Atrial Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 252-261.	1.7	58
21	Relation of Digoxin Use in Atrial Fibrillation and the Risk of All-Cause Mortality in Patients ≥65 Years of Age With Versus Without Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 401-406.	1.6	55
22	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. <i>Circulation</i> , 2022, 145, 1693-1704.	1.6	54
23	Air Medical Transport of Cardiac Patients *. <i>Chest</i> , 2003, 124, 1937-1945.	0.8	51
24	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018, 197, 124-132.	2.7	50
25	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007437.	4.8	49
26	Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 18.	1.7	47
27	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1207-1218.	1.7	43
28	Anticoagulation Management Pre- and Post Atrial Fibrillation Ablation: A Survey of Canadian Centres. <i>Canadian Journal of Cardiology</i> , 2013, 29, 219-223.	1.7	37
29	Meta-Analysis of Continuous Oral Anticoagulants Versus Heparin Bridging in Patients Undergoing CIED Surgery: Reappraisal after the BRUISE Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 417-423.	1.2	36
30	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. <i>Canadian Journal of Cardiology</i> , 2014, 30, 231-236.	1.7	35
31	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.7	34
32	Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2007, 167, 1648.	3.8	33
33	Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. <i>Heart Rhythm</i> , 2009, 6, 1276-1279.	0.7	33
34	Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. <i>Current Opinion in Cardiology</i> , 2009, 24, 82-87.	1.8	31
35	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	31
36	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 152-158.	4.8	29

#	ARTICLE	IF	CITATIONS
37	2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients With Structural Heart Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 822-836.	1.7	28
38	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 660-668.	3.2	27
39	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1069-1077.	1.7	27
40	Trends in US Hospitalization Rates and Rhythm Control Therapies Following Publication of the AFFIRM and RACE Trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 548-553.	1.7	25
41	Psychological effects of implantable cardioverter defibrillator shocks. A review of study methods. <i>Frontiers in Psychology</i> , 2015, 6, 39.	2.1	25
42	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007545.	4.8	25
43	Management of Anticoagulation Around Pacemaker and Defibrillator Surgery. <i>Circulation</i> , 2014, 129, 2062-2065.	1.6	24
44	Prognostic value of pulmonary vein size in prediction of atrial fibrillation recurrence after pulmonary vein isolation: a cardiovascular magnetic resonance study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 49.	3.3	24
45	Left atrial ablation pendulum swinging back towards the pulmonary veins The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2005, 26, 2484-2486.	2.2	23
46	Bi-directional electrical pulmonary vein isolation as an endpoint for ablation of paroxysmal atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2006, 17, 111-117.	1.3	23
47	Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: The Canadian Heart Rhythm Society Device Advisory Committee. <i>Heart Rhythm</i> , 2009, 6, 474-477.	0.7	22
48	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	1.7	22
49	Implications of Frailty in Elderly Patients With Electrophysiological Conditions. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 288-294.	3.2	22
50	Subclinical Atrial Fibrillation and Risk of Stroke: Past, Present and Future. <i>Medicina (Lithuania)</i> , 2019, 55, 611.	2.0	21
51	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017, 19, euw116.	1.7	20
52	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. <i>American Heart Journal</i> , 2021, 234, 90-100.	2.7	20
53	Diagnosis and management of supraventricular tachycardias. <i>Cmaj</i> , 2016, 188, E466-E473.	2.0	19
54	Management of antithrombotic therapy during cardiac implantable device surgery. <i>Journal of Arrhythmia</i> , 2016, 32, 163-169.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Venous Thrombosis After Electrophysiology Procedures. <i>Chest</i> , 2017, 152, 574-586.	0.8	19
56	Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 43-48.	1.0	18
57	Prognostic value of atrial fibrillation inducibility after right atrial flutter ablation. <i>Heart Rhythm</i> , 2014, 11, 1870-1876.	0.7	18
58	Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients) <i>TJ ETQq0 0 QrBT /Overlock 10 T</i>		
59	Catheter ablation for the treatment of atrial fibrillation is associated with a reduction in health care resource utilization. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 733-741.	1.7	18
60	Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005663.	4.8	18
61	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	1.7	16
62	Warfarin Treatment and Outcomes of Patients With Atrial Fibrillation in Rural and Urban Settings. <i>Journal of Rural Health</i> , 2015, 31, 310-315.	2.9	15
63	Long-term risk of stroke and bleeding post-atrial fibrillation ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1355-1362.	1.7	15
64	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	3.2	15
65	Population-Based Evaluation of Major Adverse Events After Catheter Ablation for Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1425-1433.	3.2	14
66	Cost Effectiveness of Continued-Warfarin Versus Heparin-Bridging Therapy During Pacemaker and Defibrillator Surgery. <i>Journal of the American College of Cardiology</i> , 2015, 65, 957-959.	2.8	13
67	Recent advances in ablation of ventricular tachycardia associated with structural heart disease. <i>Current Opinion in Cardiology</i> , 2016, 31, 64-71.	1.8	13
68	Cardiac resynchronization therapy reprogramming to improve electrical synchrony in patients with existing devices. <i>Journal of Electrocardiology</i> , 2019, 56, 94-99.	0.9	13
69	Therapy for ventricular arrhythmias in structural heart disease: a multifaceted challenge. <i>Journal of Physiology</i> , 2016, 594, 2431-2443.	2.9	12
70	Prognostic Value of Noninducibility on Outcomes of Ventricular Tachycardia Ablation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 911-919.	3.2	12
71	Effectiveness of catheter ablation of atrial fibrillation The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> . <i>European Heart Journal</i> , 2006, 27, 130-131.	2.2	10
72	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. <i>International Journal of Cardiology</i> , 2019, 288, 87-93.	1.7	10

#	ARTICLE	IF	CITATIONS
73	Predicting response to cardiac resynchronization therapy: Use of strict left bundle branch block criteria. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 431-438.	1.2	10
74	Sustained quality-of-life improvement post-cryoballoon ablation in patients with paroxysmal atrial fibrillation: Results from the STOP-AF Post-Approval Study. <i>Heart Rhythm</i> , 2020, 17, 485-491.	0.7	10
75	Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. <i>Europace</i> , 2020, 22, 739-747.	1.7	10
76	A Historical Perspective on the Role of Functional Lines of Block in the Reentrant Circuit of Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 490-496.	1.2	9
77	Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: A meta-analysis. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 276-281.	1.0	9
78	Optimization of Chronic Cardiac Resynchronization Therapy Using Fusion Pacing Algorithm Improves Echocardiographic Response. <i>CJC Open</i> , 2020, 2, 62-70.	1.5	9
79	Effect of Amiodarone Dose on the Risk of Permanent Pacemaker Insertion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2004, 27, 1519-1525.	1.2	8
80	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 582-587.	1.6	8
81	Formation of a national network for rapid response to device and lead advisories: The Canadian Heart Rhythm Society Device Advisory Committee. <i>Canadian Journal of Cardiology</i> , 2009, 25, 403-405.	1.7	7
82	Nonphysiologic noise early after defibrillator implantation in Canada: Incidence and implications. <i>Heart Rhythm</i> , 2012, 9, 378-382.	0.7	7
83	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	1.7	7
84	Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography. <i>CJC Open</i> , 2019, 1, 231-237.	1.5	6
85	Fusion pacing in patients with right bundle branch block who undergo cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2021, 64, 66-71.	0.9	6
86	Guidance for catheter ablation of ventricular arrhythmia. <i>Medical and Biological Engineering and Computing</i> , 2009, 47, 241-243.	2.8	5
87	Prevention of venous thrombosis after electrophysiology procedures: a survey of national practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 357-363.	1.3	5
88	Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients. <i>Pharmacological Research</i> , 2019, 143, 133-142.	7.1	5
89	Catheter Ablation of Atrial Fibrillation: Current and Evolving Indications. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1685-1689.	1.7	5
90	Defining the pattern of initiation of monomorphic ventricular tachycardia using the beat-to-beat intervals recorded on implantable cardioverter defibrillators from the RAFT study: A computer-based algorithm. <i>Journal of Electrocardiology</i> , 2018, 51, 470-474.	0.9	4

#	ARTICLE	IF	CITATIONS
91	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. <i>Heart Rhythm</i> , 2018, 15, 524-529.	0.7	4
92	Population-Level evaluation of complications after catheter ablation in patients with atrial fibrillation and heart failure. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2678-2685.	1.7	4
93	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab513.	0.9	4
94	Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. <i>Europace</i> , 2022, 24, 1112-1118.	1.7	4
95	Population-Level Sex Differences and Predictors for Treatment With Catheter Ablation in Patients With Atrial Fibrillation and Heart Failure. <i>CJC Open</i> , 2020, 2, 85-93.	1.5	3
96	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, , CIRCEP121010462.	4.8	3
97	Response to Letter Regarding Article, "Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis". <i>Circulation</i> , 2014, 130, e428-9.	1.6	2
98	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	4.8	2
99	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. <i>Canadian Journal of Cardiology</i> , 2018, 34, 808-811.	1.7	2
100	Maximizing biventricular pacing in patients with rate-controlled atrial fibrillation using ventricular sense response. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1069-1072.	1.2	2
101	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alert—a multicentre cohort. <i>Europace</i> , 2021, 23, 1319-1323.	1.7	2
102	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients ≥75 Years Versus <75 Years Receiving Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2018, 121, 975-980.	1.6	1
103	Pulmonary embolism after electrophysiology procedures: Incidence from a single centre registry. <i>Thrombosis Research</i> , 2018, 167, 125-127.	1.7	1
104	Pattern of initiation of monomorphic ventricular tachycardia and implications on tachycardia mechanism. <i>Minerva Cardiology and Angiology</i> , 2017, 65, 357-368.	0.7	1
105	The use of adenosine to identify dormant conduction after accessory pathway ablation: a single center experience and literature review. <i>American Journal of Cardiovascular Disease</i> , 2019, 9, 84-90.	0.5	1
106	Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial. <i>Europace</i> , 2022, 24, 948-958.	1.7	1
107	Long-term outcomes of catheter ablation for atrial fibrillation: It's a matter of time. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1048-1050.	1.7	0
108	Non-vitamin K Antagonists and Cardiac Implantable Electronic Devices. , 2021, , 211-223.		0

#	ARTICLE	IF	CITATIONS
109	Direct Oral Anticoagulants and Atrial Fibrillation Ablation. , 2021, , 225-234.		0
110	Abstract 21033: Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A Vanish Substudy. Circulation, 2017, 136, .	1.6	0